Anti-Vascular Endothelial Growth Factor Treatment Patterns and Outcomes in Retinal Vein Occlusion in Routine Clinical Practice.

Autor:	Xu CM, Kim E, Valentim CCS, Seth K, Muste JC, Perkins S, Singh RP
Jazyk:	angličtina
Zdroj:	Ophthalmic surgery, lasers & imaging retina [Ophthalmic Surg Lasers Imaging Retina] 2022 Nov; Vol. 53 (11), pp. 626-633. Date of Electronic Publication: 2022 Nov 01.
DOI:	10.3928/23258160-20221026-02
Abstrakt:	Background and Objective: To characterize treatment patterns for retinal vein occlusion (RVO)-related macular edema (ME) in routine clinical practice and its impact on long-term best-corrected visual acuity (BCVA) and central subfield thickness (CST). Patients and Methods: Retrospective study of 365 eyes with branch RVO (BRVO) or central/hemi-RVO (CRVO/HRVO)-related ME between 2003 and 2020. Regression analysis identified factors associated with maintenance injection interval (MII). Subgroup analysis compared outcomes between different MIIs. Results: 51.3% of BRVO patients received injections ≤q8 weeks, 26.4% received injections q8-12 weeks, and 22.3% received injections >q12 weeks. 45.2% of CRVO/HRVO patients received injections ≤q8 weeks, 32.1% received injections q8-12 weeks, and 22.6% received injections >q12 weeks. Age, diabetes, and baseline CST were found to predict MII. There was no significant difference in BCVA and CST at baseline, 12, or 24 months in all MII groups in BRVO and CRVO/HRVO. Conclusion: There exists a significant heterogeneity in anti-VEGF treatment frequency for RVO-associated ME in routine clinical practice. [ Ophthalmic Surg Lasers Imaging Retina 2022;53:626-633.] .
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu